Trial Profile
A placebo-controlled, randomised, double-blind, single dose proof of concept study of DIMS-0150 [Kappaproct], in steroid resistant or steroid dependent patients with ulcerative colitis of mild to moderate degree.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 12 Aug 2014
Price :
$35
*
At a glance
- Drugs Cobitolimod (Primary)
- Indications Ulcerative colitis
- Focus Pharmacodynamics; Proof of concept; Therapeutic Use
- Sponsors InDex Pharmaceuticals
- 12 Aug 2014 New trial record